Hemodialysis patients make long-lived antibodies against SARS-CoV-2 that may be associated with reduced reinfection.
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections have a devastating effect on patients receiving hemodialysis. To what extent infection-induced antibody responses are maintained, or protective, is unknown. This study describes the evolution of antibodies against the SARS-CoV-2 spike protein in a cohort of 990 patients on hemodialysis. During the first wave of the pandemic, 26% of patients had developed antispike SARS-CoV-2 antibodies. Fewer PCR-confirmed second-wave infections were observed in patients with pre-existing antibodies (4.2%) than those without antibodies (11.4%). This study shows that SARS-CoV-2 antibodies in patients on hemodialysis are well maintained and associate with reduced risk of subsequent SARS-CoV-2 infection.
Citations
Altmetric:
Date
2021-08-02
Type
Article
Subject
Health services. Management, Microbiology. Immunology
Collections
Citation
Banham GD, Godlee A, Faustini SE, Cunningham AF, Richter A, Harper L; COVID-HD Birmingham Study Group. Hemodialysis Patients Make Long-Lived Antibodies against SARS-CoV-2 that May Be Associated with Reduced Reinfection. J Am Soc Nephrol. 2021 Sep;32(9):2140-2142. doi: 10.1681/ASN.2021020188. Epub 2021 Aug 2
Journal / Source Title
Journal of the American Society of Nephrology
DOI
10.1681/ASN.2021020188
PMID
34341181
Publisher
Wolters Kluwer Health
Publisher’s URL
http://www.jasn.org/